A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide

Trial Profile

A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs MB 66 (Primary)
  • Indications Herpes simplex virus infections; HIV infections
  • Focus Adverse reactions
  • Acronyms VAST
  • Sponsors Leaf Biopharmaceutical
  • Most Recent Events

    • 26 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2018.
    • 07 Sep 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Apr 2017.
    • 11 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top